Gotowa bibliografia na temat „Coronary heart disease Molecular aspects”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Coronary heart disease Molecular aspects”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Coronary heart disease Molecular aspects"
Pries, Axel R., Wolfgang M. Kuebler i Helmut Habazettl. "Coronary Microcirculation in Ischemic Heart Disease". Current Pharmaceutical Design 24, nr 25 (8.11.2018): 2893–99. http://dx.doi.org/10.2174/1381612824666180625142341.
Pełny tekst źródłaCavarretta, Elena, i Giacomo Frati. "MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena?" BioMed Research International 2016 (2016): 1–10. http://dx.doi.org/10.1155/2016/2150763.
Pełny tekst źródłaSantosa Putra, Iwan Cahyo, i William Kamarullah. "Diving deep into chelation therapy for coronary artery disease: a review". International Journal of Basic & Clinical Pharmacology 8, nr 12 (25.11.2019): 2769. http://dx.doi.org/10.18203/2319-2003.ijbcp20195295.
Pełny tekst źródłaKhaw, Kay-Tee. "Epidemiological aspects of ageing". Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 352, nr 1363 (29.12.1997): 1829–35. http://dx.doi.org/10.1098/rstb.1997.0168.
Pełny tekst źródłaMalekmohammad, Khojasteh, Robert D. E. Sewell i Mahmoud Rafieian-Kopaei. "Antioxidants and Atherosclerosis: Mechanistic Aspects". Biomolecules 9, nr 8 (25.07.2019): 301. http://dx.doi.org/10.3390/biom9080301.
Pełny tekst źródłaSimmonds, Steven J., Ilona Cuijpers, Stephane Heymans i Elizabeth A. V. Jones. "Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding". Cells 9, nr 1 (18.01.2020): 242. http://dx.doi.org/10.3390/cells9010242.
Pełny tekst źródłaGolukhova, E. Z., O. I. Gromova, R. A. Shomahov, N. I. Bulaeva i L. A. Bockeria. "Monogenec Arrhythmic Syndromes: From Molecular and Genetic Aspects to Bedside". Acta Naturae 8, nr 2 (15.06.2016): 62–74. http://dx.doi.org/10.32607/20758251-2016-8-2-62-74.
Pełny tekst źródłaBastos, Marcelo B., Maarten P. van Wiechen i Nicolas M. Van Mieghem. "PulseCath iVAC2L: next-generation pulsatile mechanical circulatory support". Future Cardiology 16, nr 2 (marzec 2020): 103–12. http://dx.doi.org/10.2217/fca-2019-0060.
Pełny tekst źródłaVentegodt, Søren, Efrat Merrick i Joav Merrick. "Clinical Holistic Medicine: The Dean Ornish Program (“Opening the Heart”) in Cardiovascular Disease". Scientific World JOURNAL 6 (2006): 1977–84. http://dx.doi.org/10.1100/tsw.2006.330.
Pełny tekst źródłaShi, Qi, Kuo Gao, Huihui Zhao, Juan Wang, Xing Zhai, Peng Lu, Jianxin Chen i Wei Wang. "Phenomics Research on Coronary Heart Disease Based on Human Phenotype Ontology". BioMed Research International 2014 (2014): 1–16. http://dx.doi.org/10.1155/2014/240284.
Pełny tekst źródłaRozprawy doktorskie na temat "Coronary heart disease Molecular aspects"
Warner, Anke Sigrid. "The expression, regulation and effects of inducible nitric oxide synthase in hibernating myocardium". Title page, contents and summary only, 2002. http://web4.library.adelaide.edu.au/theses/09PH/09phw279.pdf.
Pełny tekst źródłaMakubalo, Zola. "Mutation screening of candidate genes and the development of polymorphic markers residing on chromosome 19q13.3, the progressive familial heart block I gene search area". Thesis, Stellenbosch : Stellenbosch University, 2000. http://hdl.handle.net/10019.1/51838.
Pełny tekst źródłaENGLISH ABSTRACT: Progressive familial heart block type I (PFHBI) is a cardiac ventricular conduction disorder of unknown cause associated with risk of sudden death, which has been described in several South African families. Clinically, PFHBI is characterised by right bundle branch block on ECG, which may progress to complete heart block, necessitating pacemaker implantation. The disease shows an autosomal dominant pattern of inheritance with evidence of genetic anticipation. Using genetic linkage analysis, the PFHBI-causative gene was mapped to a 10 eentimorgan (cM) gene-rich area of chromosome (C) 19q13.3, which has, subsequently, been reduced to 7cM by fine mapping with polymorphic dinucleotide (CA)n short tandem repeat (STR) markers. Several attractive candidate genes, including muscle glycogen synthase (GSY 1) and histidine-rich calcium binding protein (HRC), lie within this region. The aim of the present study was two-fold: 1) to identify and characterise tetranucleotide (AAAT)n STRs within the PFHBI critical region that could be developed as polymorphic markers for use in genetic fine mapping and 2) to screen selected regions of GSY 1and HRC, positional candidate genes, for the presence ofPFHBI-causing mutation(s). Cosmids harbouring CI9q13.3 insert DNA were screened for the presence of (AAAT)n STRs by dot blot and Southern blot hybridisation using a radiolabelled (AAAT)lO oligonucleotide probe. To characterise the harboured (AAAT)n STRs, the positively hybridising fragments identified by Southern blot were sub-cloned, sequenced and primers designed from the unique repeat-flanking sequences. These primers were used to genotype the (AAAT)n repeat locus to assess its polymorphic nature in a panel of unrelated individuals. Alternatively, vectorette PCR, a rapid method of identifying repeat sequences and obtaining the flanking sequences in large inserts, was employed to develop polymorphic markers from the positively hybridising clones. Selected exons of GSY1 and HRC were screened for the presence of potentially disease-causing mutations by PCR-SSCP analysis and direct sequencing, respectively, in PFHBI-affected and unaffected family members. Of the available cosmid clones that gave strong signals on dot blot and Southern blot hybridisation, three, 29395, 24493 and 20381, were located within the critical PFHBI area and were used for marker development. An interrupted (AAAT)n repeat motif (n less than 5) was identified in cosmid 29395, however, the repeat locus was not polymorphic in the tested population. No (AAAT)n motif, single or repeated was observed in the partial sequence of the sub-cloned fragment of cosmid 24493. Using vectorette peR, no repeated (AAAT)n motif was identified on sequencing the generated products in either cosmid 24493 or 2038l. However, diffuse single AAAT motifs were detected in both cosmids. Exons 4, 5, 11, 12 and 16 of GSY 1, containing domains that are conserved across species, and the conserved eterminus- encoding exons 2-6 of HRC were selected for screening for potential PFHBI-causing mutation(s). However, no sequence variations were detected. The interrupted (AAAT)n repeat identified in cosmid 29395 was not polymorphic, which confirmed reports that complex repeats, especially those containing AAAT motifs of less than 6 repeats, are not polymorphic. One possible explanation for the absence of a repeated AAAT motif in cosmids 24493 and 20381, which both gave positive hybridisation signals, is that the low annealing temperature of the AfT -rich repeat-anchored primers used in vectorette peR may have resulted in transient annealing to the diffuse single AAAT motifs detected on sequencing. The screened regions of candidate genes GSYI and HRC were excluded from carrying the disease-causing mutation(s). The availability of new sequence data generated by the Human Genome Project will influence future strategies to identify the PFHBI gene. Electronic searches will allow identification of STR sequences for development of polymorphic markers and gene annotation will allow selection of new candidate genes for mutation screening.
AFRIKAANSE OPSOMMING: Sien volteks vir opsomming
Sarwar, Nadeem. "Emerging molecular and genetic risk factors for coronary heart disease". Thesis, University of Cambridge, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.611549.
Pełny tekst źródłaAshton, Emma Louise, i emma ashton@deakin edu au. "Effects of dietary constituents on coronary heart disease risk factors". Deakin University. School of Biological and Chemical Sciences, 2000. http://tux.lib.deakin.edu.au./adt-VDU/public/adt-VDU20061207.153511.
Pełny tekst źródłaAbdul-Majid, Hariyati Shahrima. "Psychological aspects of recovery from coronary heart disease among patients in Malaysia". Thesis, University of Surrey, 2001. http://epubs.surrey.ac.uk/843015/.
Pełny tekst źródłaHo, Lai-yi Ada, i 何麗儀. "Does social support influence coronary heart disease prognosis?: a meta-analysis". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2005. http://hub.hku.hk/bib/B39724116.
Pełny tekst źródłaJenneke, Cindy A. N. "The effect of dietary patterns on risk factors for CHD : a comparative study of students residing at the Adventist International Institute of Advanced Studies in the Philippines". Thesis, Link to online version, 2006. http://hdl.handle.net/10019/554.
Pełny tekst źródłaCao, Fei. "Chlamydia pneumoniae, toll-like receptors and pathogenesis of atherosclerotic heart disease". View the abstract Download the full-text PDF version (on campus access only), 2007. http://etd.utmem.edu/ABSTRACTS/2007-022-Cao-index.html.
Pełny tekst źródłaTitle from title page screen (viewed on May 16, 2008 ). Research advisor: Gerald I. Byrne, Ph.D. Document formatted into pages (xi, 114 p. : ill.). Vita. Abstract. Includes bibliographical references (p. 65-107).
Buri, Robert J. (Robert John). "The Role of Anger/Hostility on Physiological and Behavioral Risk Factors for Coronary Heart Disease". Thesis, University of North Texas, 1995. https://digital.library.unt.edu/ark:/67531/metadc278222/.
Pełny tekst źródłaPepe, Salvatore. "The influence of dietary fatty acids on cardiac function /". Title page, table of contents and abstract only, 1991. http://web4.library.adelaide.edu.au/theses/09PH/09php4201.pdf.
Pełny tekst źródłaKsiążki na temat "Coronary heart disease Molecular aspects"
Vlodaver, Zeev. Coronary Heart Disease: Clinical, Pathological, Imaging, and Molecular Profiles. Boston, MA: Springer US, 2012.
Znajdź pełny tekst źródłaS, Leon Arthur, red. Coronary heart disease: A behavorial perspective. Champaign, Ill: Research Press, 1992.
Znajdź pełny tekst źródłaBudnick, Herbert N. Heart to heart: A guide to the psychological aspects of heart disease. Santa Fe, NM: Health Press, 1991.
Znajdź pełny tekst źródłaThompson, David R. Counselling the coronary patient and partner. Harrow: Scutari Press, 1990.
Znajdź pełny tekst źródłaKris-Etherton, P. M. Trans fatty acids and coronary heart disease risk. Washington, D.C: ILSI Press, 1995.
Znajdź pełny tekst źródłaMogadam, Michael. Choosing foods for a healthy heart. Yonkers, N.Y: Consumer Reports Books, 1993.
Znajdź pełny tekst źródłaMangiapane, E. H. Diet, lipoproteins and coronary heart disease: A biochemical perspective. Nottingham: Nottingham University Press, 1998.
Znajdź pełny tekst źródła1919-, Hallgren Bo, i Svenska läkaresällskapet, red. Diet and prevention of coronary heart disease and cancer. New York: Raven Press, 1986.
Znajdź pełny tekst źródłaHealthy heart handbook: How to prevent and reverse heart disease ... Makaha, Hawaii: Healing Heart Foundation, 1994.
Znajdź pełny tekst źródłaFriedman, Meyer. Treating type A behavior and your heart. New York: Fawcett Crest, 1985.
Znajdź pełny tekst źródłaCzęści książek na temat "Coronary heart disease Molecular aspects"
Lemmer, Björn, i Klaus Witte. "Chronopharmacological aspects of coronary heart disease". W Developments in Cardiovascular Medicine, 295–308. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-1577-0_19.
Pełny tekst źródłaGalton, David J. "Molecular Genetics of Coronary Heart Disease". W Advances in Experimental Medicine and Biology, 95–105. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-0733-4_13.
Pełny tekst źródłaAssmann, G., A. von Eckardstein i H. Funke. "Apolipoproteins, Reverse Cholesterol Transport and Coronary Heart Disease". W Cellular and Molecular Biology of Atherosclerosis, 159–66. London: Springer London, 1992. http://dx.doi.org/10.1007/978-1-4471-1909-8_15.
Pełny tekst źródłaHeusch, Gerd, i B. D. Guth. "New aspects on the pathophysiology of coronary heart disease". W Treatment with Gallopamil, 65–84. Heidelberg: Steinkopff, 1989. http://dx.doi.org/10.1007/978-3-642-85376-0_7.
Pełny tekst źródłaPatsch, J. R., i G. Miesenboeck. "High-Density Lipoprotein Cholesterol, Triglycerides and Coronary Heart Disease". W Cellular and Molecular Biology of Atherosclerosis, 153–57. London: Springer London, 1992. http://dx.doi.org/10.1007/978-1-4471-1909-8_14.
Pełny tekst źródłaSoubrier, F., X. Jeunemaître, B. Rigat, F. Cambien i P. Corvol. "Molecular Genetics and Familial Arterial Hypertension". W Genetic Approaches to Coronary Heart Disease and Hypertension, 27–37. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-76891-0_4.
Pełny tekst źródłaCalabresi, Laura, i Guido Francheschini. "Genetic LCAT Deficiency: Molecular Diagnosis, Plasma Lipids, and Atherosclerosis". W High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease, 89–93. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1059-2_11.
Pełny tekst źródłaBerg, Kåre. "Genetics of Coronary Heart Disease and its Risk Factors". W Ciba Foundation Symposium 130 - Molecular Approaches to Human Polygenic Disease, 14–33. Chichester, UK: John Wiley & Sons, Ltd., 2007. http://dx.doi.org/10.1002/9780470513507.ch3.
Pełny tekst źródłater Keurs, Henk E. D. J. "Macroscopic and Microscopic Aspects of Cardiac Dysfunction in Congestive Heart Failure". W Molecular Defects in Cardiovascular Disease, 95–107. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-7130-2_8.
Pełny tekst źródłaInagaki, Tadakatsu, Hirotsugu Tsuchimochi, James T. Pearson, Daryl O. Schwenke, Keiji Umetani, Mikiyasu Shirai i Yoshikazu Nakaoka. "Impaired Right Coronary Vasodilator Function in Pulmonary Hypertensive Rats Assessed by In Vivo Synchrotron Microangiography". W Molecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension, 193–95. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-1185-1_25.
Pełny tekst źródłaStreszczenia konferencji na temat "Coronary heart disease Molecular aspects"
Tao, Weiye, Laiyou Wang, Guohua Cheng, Jun Liu i Langping Tang. "Mechanism of Sini Decoction on Coronary Heart Disease in Molecular Level". W 2nd International Conference on Computer and Information Applications (ICCIA 2012). Paris, France: Atlantis Press, 2012. http://dx.doi.org/10.2991/iccia.2012.144.
Pełny tekst źródłaUzbekova, Nelly, Sergey Kityan i Nodira Badalbaeva. "USE OF PLETHYSMOGRAPHY IN THE ASSESSMENT OF THE ARTERIAL WALL IN PERSONS WITH CORONARY HEART DISEASE". W THEORETICAL AND PRACTICAL ASPECTS OF MODERN SCIENTIFIC RESEARCH. European Scientific Platform, 2021. http://dx.doi.org/10.36074/logos-30.04.2021.v2.43.
Pełny tekst źródłaFalk, E. A. "UNSTABLE ANGINA PECTORIS: PATHOLOGIC ASPECTS". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643711.
Pełny tekst źródłaDenisova, Tatyana P., Lidia I. Malinova i Igor A. Malinov. "Physical and mathematical aspects of blood-glucose- and insulin-level kinetics in patients with coronary heart disease and high risk of its development". W Saratov Fall Meeting 2000, redaktor Valery V. Tuchin. SPIE, 2001. http://dx.doi.org/10.1117/12.431540.
Pełny tekst źródłaZhang, Song, John A. Crow, Robert C. Cooper, Ronald M. McLaughlin, Shane Burgess, Ali Borazjani i Jun Liao. "Detection of Myocardial Fiber Disruption in Artificial Lesions With 3D DT-MRI Tract Models". W ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-193121.
Pełny tekst źródłaPoniewierski, M., M. Barthels i H. Poliwoda. "THE SAFETY AND EFFICACY OF A LOW MOLECULAR WEIGHT HEPARIN (FRAGMIN) IN THE PREVENTION OF DEEP VEIN THROMBOSIS IN MEDICAL PATIENTS: A RANDOMIZED DOUBLE-BLIND TRIAL". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643224.
Pełny tekst źródła